These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8377088)

  • 1. Factorial design-based optimization of the formulation of isosorbide-5-mononitrate microcapsules.
    Farivar M; Kaş HS; Oner L; Hincal AA
    J Microencapsul; 1993; 10(3):309-17. PubMed ID: 8377088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenytoin sodium microcapsules: bench scale formulation, process characterization and release kinetics.
    Yazici E; Oner L; Kaş HS; Hincal AA
    Pharm Dev Technol; 1996 Jul; 1(2):175-83. PubMed ID: 9552344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the properties of ethylcellulose-cellulose triacetate microcapsules containing theophylline prepared by different microencapsulation techniques.
    Wu JC; Jean WJ; Chen H
    J Microencapsul; 1994; 11(5):507-18. PubMed ID: 7815268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on preparation of isosorbide-5-mononitrate pulsatile controlled-release pellets and various influence factors].
    Wang R; Huang G; Fang Z
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Aug; 25(4):885-8. PubMed ID: 18788301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation development and in vitro evaluation of theophylline microcapsules.
    Ahmad M; Akhtar N; Murtaza G; Hussain SW
    Pak J Pharm Sci; 2012 Jan; 25(1):15-9. PubMed ID: 22186304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release dosage form of phenylpropanolamine hydrochloride. Part II: Formulation and in vitro release kinetics from tableted microcapsules.
    Sevgi F; Ozyazici M; Güneri T
    J Microencapsul; 1994; 11(3):335-44. PubMed ID: 8064557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation.
    Li X; Jiang Q; Du L; Li Y; Li M
    Pharmazie; 2014 Feb; 69(2):109-16. PubMed ID: 24640599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isosorbide-5-mononitrate (5-ISMN) sustained-release pellets prepared by double layer coating for reducing 5-ISMN migration and sublimation.
    Li G; Han D; Guan T; Zhao X; He H; Tang X
    Int J Pharm; 2010 Nov; 400(1-2):138-44. PubMed ID: 20826202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained-release dosage form of phenylpropanolamine hydrochloride. Part I: Microencapsulation and in vitro release kinetics.
    Sevgi F; Ozyazici M; Güneri T
    J Microencapsul; 1994; 11(3):327-34. PubMed ID: 8064556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and study of release kinetics of rosin pentaerythritol ester microcapsules.
    Sheorey DS; Dorle AK
    J Microencapsul; 1994; 11(1):11-7. PubMed ID: 8138870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization and evaluation of time-dependent tablets comprising an immediate and sustained release profile using artificial neural network.
    Xie H; Gan Y; Ma S; Gan L; Chen Q
    Drug Dev Ind Pharm; 2008 Apr; 34(4):363-72. PubMed ID: 18401778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate.
    Liu Y; Liu S; Dai Q
    Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):55-60. PubMed ID: 19122316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemically cross-linked poly(acrylic-co-vinylsulfonic) acid hydrogel for the delivery of isosorbide mononitrate.
    Hussain T; Ansari M; Ranjha NM; Khan IU; Shahzad Y
    ScientificWorldJournal; 2013; 2013():340737. PubMed ID: 24250265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
    Skutta T; Böttcher B; Brandt L
    Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.